19,408 Shares in CONMED Corporation $CNMD Bought by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG purchased a new stake in CONMED Corporation (NYSE:CNMD) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 19,408 shares of the company’s stock, valued at approximately $913,000. B. Metzler seel. Sohn & Co. AG owned approximately 0.06% of CONMED as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of CNMD. Vanguard Group Inc. increased its holdings in CONMED by 1.8% in the third quarter. Vanguard Group Inc. now owns 3,610,906 shares of the company’s stock worth $169,821,000 after buying an additional 62,917 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of CONMED by 19.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,296,776 shares of the company’s stock worth $60,984,000 after purchasing an additional 214,126 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of CONMED by 2.8% in the second quarter. Geode Capital Management LLC now owns 734,529 shares of the company’s stock valued at $38,259,000 after acquiring an additional 19,944 shares during the period. Cooke & Bieler LP boosted its holdings in CONMED by 0.8% in the 3rd quarter. Cooke & Bieler LP now owns 704,323 shares of the company’s stock valued at $33,124,000 after purchasing an additional 5,250 shares during the period. Finally, Tributary Capital Management LLC bought a new stake in shares of CONMED in the third quarter valued at about $19,549,000.

Analysts Set New Price Targets

A number of analysts recently weighed in on CNMD shares. Wells Fargo & Company upped their target price on shares of CONMED from $41.00 to $42.00 and gave the company an “equal weight” rating in a research note on Thursday, January 29th. Bank of America cut their price target on CONMED from $65.00 to $52.00 and set a “neutral” rating for the company in a report on Monday, December 8th. Weiss Ratings reiterated a “sell (d+)” rating on shares of CONMED in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of CONMED from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of CONMED in a report on Thursday, January 29th. One research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $52.83.

CONMED Stock Down 0.1%

CONMED stock opened at $38.43 on Thursday. CONMED Corporation has a fifty-two week low of $35.37 and a fifty-two week high of $62.41. The company’s 50-day moving average is $41.95 and its 200-day moving average is $44.49. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.14 and a quick ratio of 1.01. The firm has a market capitalization of $1.18 billion, a PE ratio of 25.45, a P/E/G ratio of 1.69 and a beta of 0.91.

CONMED (NYSE:CNMD) last released its quarterly earnings results on Wednesday, January 28th. The company reported $1.43 EPS for the quarter, topping analysts’ consensus estimates of $1.32 by $0.11. CONMED had a net margin of 3.42% and a return on equity of 14.23%. The business had revenue of $373.20 million for the quarter, compared to analyst estimates of $366.88 million. During the same period last year, the firm earned $1.34 earnings per share. CONMED’s revenue for the quarter was up 7.9% compared to the same quarter last year. Sell-side analysts anticipate that CONMED Corporation will post 4.35 earnings per share for the current year.

CONMED Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.